25 May 2013
Keywords: valeant, licenses, canada, rights, xyrem, jazz, pharmaceuticals
Article | 22 January 2007
Jazz Pharmaceuticals has signed an agreement licensing the Canadian marketing rights for its oral drug Xyrem (sodium oxybate) to fellow
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 January 2007
24 May 2013
© 2013 thepharmaletter.com